4
Total investments
1
Early stage
1
Mid stage
1
Late stage
4y
Years active
Portfolio
4 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Apr 2023
Rviewer allows you to solve technical challenges similar to those you would find in any company to test your coding skills and gain confidence if you want to change your current job. We share memes too 🙃
Join our dev community 🤙
Join our Discord 👉🏽 https://bit.ly/3MCiqTC
Seed Investor
Mar 2023
El software inmobiliario de gestión de propiedades todo en uno que responda a tus necesidades.
Investor
Jan 2023
Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting big market indications in immunology and oncology. After successful proof-of-concept studies in early clinical phases, seeking license agreements with pharmaceutical companies for further clinical development and commercialization. ---- PIPELINE: ---- Two of Oncostellaes drug candidates have reached advanced development stages and are currently being evaluated in clinical studies in patients: OST-122 is a safe, non-systemic JAK inhibitor for the treatment of Ulcerative Colitis (Phase 2a), and OST-499 is a GR antagonist for the treatment of colon cancer and other solid tumors (Phase 1). Positive data on safety and efficacy that are expected to be available by the end of 2023 would provide outlicensing opportunities.
Investor
Oct 2022
MIM HABITS has created the first bread developed by scientists enriched with our patented postbiotic complex: MIM COMPLEX, to help restore the balance of the intestinal microbiota.
MIM HABITS is the revolution that the foodtech world was waiting for, putting science and tradition at the service of your well-being.
In each recipe we combine centuries-old know-how of sourdough with years of scientific research into microbiota and immune health.
The MIM COMPLEX formula promotes the presence and diversity of beneficial bacteria for the intestinal ecosystem.
Are you ready for a paradigm shift in the food world?
Experience · 8 entries
All (8)
Investments (4)
Founder (3)
2026
Co-Founder
Apr 2026
The Deep Tech Bridge: Korea (+82) 🔗 Spain (+34)
Nexus 8234 is a business and technology catalyst designed to bridge the gap between Asia and Europe’s most dynamic ecosystems. We don’t just advise; we execute.
We serve as the operational nexus for creating Joint Ventures, landing Deep Tech, and opening strategic trade corridors. Our mission is to integrate talent, capital, and technology to consolidate a global community leading the sectors of technological sovereignty.
Through high-level missions and co-innovation programs with global partners, we transform bi-national intellectual property into world-scale assets.
Nexus 8234: Connecting Innovation. Building the Future.
2025
Executive Director
Oct 2025
Startups.st Venture Capital nos dedicamos a catalizar el potencial de las startups más prometedoras, liderando el camino hacia un futuro más innovador apoyado en las capacidades de todas las regiones. Somos más que un vehiculo de inversión, somos facilitadores de crecimiento regional y de startups, apoyando a los emprendedores más audaces de todas las industrias.
2023
CEO & Founder
Oct 2023
A network for entrepreneurs building in stealth.
Submit your information here so investors can find you:
harmonic.ai/get-discovered
Investor
Apr 2023
Rviewer allows you to solve technical challenges similar to those you would find in any company to test your coding skills and gain confidence if you want to change your current job. We share memes too 🙃
Join our dev community 🤙
Join our Discord 👉🏽 https://bit.ly/3MCiqTC
Seed Investor
Mar 2023
El software inmobiliario de gestión de propiedades todo en uno que responda a tus necesidades.
Show all 8 entries ↓
Investment activity
2022–2023 · 4 investments
Recent (last 2 years)Earlier